The Trump administration is continuing its push to revise federal guidelines to delay the hepatitis B vaccine newborn dose for most children. This comes despite a failed attempt to do so at the most recent meeting of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices. Both President Donald Trump and some…
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
In Medicare Physician Fee Schedule Final Rules from recent years, the administration made changes to Medicare payment policies for certain dental services, in addition to other payment and policy changes. The 2023 rule clarified CMS’s interpretation of when medically necessary dental services can be covered and codified certain payment policies, and the 2023, 2024, and…
Other ideas that emerged from fall 2023 summit meeting were a task force on primary care and health equity and a state scorecard on primary care
The KFF-Washington Post partnership Survey of Parents explores experiences and views pertaining to childhood vaccines. The Survey of Parents also sheds light on school vaccination requirements, views on federal health agencies and policy changes, and the views of parents with children diagnosed with autism spectrum disorder. This poll comes as the Trump administration revamps federal…
This fact sheet explores the history, funding, and future outlook of the President’s Emergency Plan for AIDS Relief (PEPFAR), the U.S. government’s major global initiative to combat HIV/AIDS.
Eikon Therapeutics’ IPO haul will support a lead program that could expand the scope of cancer immunotherapy. Eikon’s stock market debut builds on growing IPO momentum, following upsized offerings from Aktis Oncology and Veradermics. The post Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials appeared first on MedCity News.
The 2026 Medicare Advantage Rate Announcement is more than just funds allocation — it signals a policy shift. It’s the next phase of value-based care and encourages every stakeholder in the MA ecosystem to rise to the occasion. The post The AI Advantage: Navigating the 2026 Medicare Advantage Rate Bump appeared first on MedCity News.
Sara McGinnis was pregnant with her second child and something felt off. Her body was swollen. She was tired and dizzy. Her husband, Bradley McGinnis, said she had told her doctor and nurses about her symptoms and even went to the emergency room when they worsened. But, Bradley said, what his wife was told in…
Neal Meropol, M.D., Flatiron’s vice president of research oncology, says that having a broader array of consumers of Flatiron’s real-world data opens up avenues to many different types of research, including on health equity